Envestnet Asset Management Inc Ligand Pharmaceuticals Inc Transaction History

Envestnet Asset Management Inc

  • $302 Billion
  • Q3 2024

A detailed history of Envestnet Asset Management Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Envestnet Asset Management Inc holds 86,285 shares of LGND stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
86,285
Previous 79,612 8.38%
Holding current value
$10.3 Million
Previous $6.71 Million 28.85%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024
BUY
$82.7 - $110.11 $551,857 - $734,764
6,673 Added 8.38%
86,285 $8.64 Million
Q2 2024

Aug 08, 2024
BUY
$68.53 - $87.91 $1.76 Million - $2.26 Million
25,717 Added 47.72%
79,612 $6.71 Million
Q1 2024

May 13, 2024
BUY
$68.64 - $89.2 $602,316 - $782,730
8,775 Added 19.45%
53,895 $3.94 Million
Q4 2023

Feb 13, 2024
BUY
$49.57 - $72.63 $66,027 - $96,743
1,332 Added 3.04%
45,120 $3.22 Million
Q3 2023

Nov 13, 2023
BUY
$58.86 - $72.67 $348,215 - $429,915
5,916 Added 15.62%
43,788 $2.62 Million
Q2 2023

Aug 04, 2023
SELL
$69.53 - $79.33 $2.39 Million - $2.73 Million
-34,423 Reduced 47.61%
37,872 $2.73 Million
Q1 2023

May 11, 2023
BUY
$65.67 - $77.08 $2.74 Million - $3.22 Million
41,784 Added 136.95%
72,295 $5.32 Million
Q4 2022

Feb 07, 2023
BUY
$61.72 - $96.74 $19,873 - $31,150
322 Added 1.07%
30,511 $2.04 Million
Q3 2022

Nov 10, 2022
BUY
$0.01 - $107.56 $35 - $384,096
3,571 Added 13.42%
30,189 $2.6 Million
Q2 2022

Aug 03, 2022
BUY
$74.52 - $117.06 $230,266 - $361,715
3,090 Added 13.13%
26,618 $2.38 Million
Q1 2022

May 04, 2022
BUY
$94.99 - $151.56 $184,755 - $294,784
1,945 Added 9.01%
23,528 $2.65 Million
Q4 2021

Feb 04, 2022
BUY
$127.69 - $165.85 $693,356 - $900,565
5,430 Added 33.62%
21,583 $3.33 Million
Q3 2021

Oct 07, 2021
BUY
$102.33 - $144.73 $105,911 - $149,795
1,035 Added 6.85%
16,153 $2.25 Million
Q2 2021

Aug 04, 2021
BUY
$113.03 - $155.64 $559,498 - $770,417
4,950 Added 48.68%
15,118 $1.98 Million
Q1 2021

May 04, 2021
SELL
$99.52 - $215.83 $329,212 - $713,965
-3,308 Reduced 24.55%
10,168 $1.55 Million
Q4 2020

Feb 02, 2021
SELL
$80.55 - $106.05 $773,843 - $1.02 Million
-9,607 Reduced 41.62%
13,476 $1.34 Million
Q3 2020

Oct 09, 2020
BUY
$89.56 - $126.72 $245,842 - $347,846
2,745 Added 13.5%
23,083 $2.2 Million
Q2 2020

Jul 08, 2020
BUY
$68.28 - $123.65 $10,173 - $18,423
149 Added 0.74%
20,338 $2.28 Million
Q1 2020

Apr 23, 2020
BUY
$63.37 - $107.88 $252,973 - $430,656
3,992 Added 24.65%
20,189 $1.47 Million
Q4 2019

Feb 11, 2020
SELL
$96.94 - $113.59 $381,652 - $447,203
-3,937 Reduced 19.55%
16,197 $1.69 Million
Q3 2019

Oct 17, 2019
SELL
$86.25 - $120.16 $59,685 - $83,150
-692 Reduced 3.32%
20,134 $2 Million
Q2 2019

Aug 02, 2019
BUY
$107.38 - $129.34 $330,086 - $397,591
3,074 Added 17.32%
20,826 $2.38 Million
Q1 2019

May 10, 2019
BUY
$105.93 - $142.47 $392,152 - $527,423
3,702 Added 26.35%
17,752 $2.23 Million
Q4 2018

Feb 13, 2019
BUY
$128.36 - $272.13 $1.8 Million - $3.82 Million
14,050 New
14,050 $1.91 Million
Q3 2018

Nov 14, 2018
SELL
$211.18 - $274.49 $1.22 Million - $1.59 Million
-5,779 Closed
0 $0
Q2 2018

Aug 10, 2018
SELL
$150.77 - $207.98 $18,092 - $24,957
-120 Reduced 2.03%
5,779 $1.2 Million
Q1 2018

May 09, 2018
SELL
$138.63 - $182.62 $115,478 - $152,122
-833 Reduced 12.37%
5,899 $968,000
Q4 2017

Feb 20, 2018
BUY
$128.36 - $147.04 $9,883 - $11,322
77 Added 1.16%
6,732 $922,000
Q3 2017

Nov 13, 2017
BUY
$120.91 - $137.94 $97,695 - $111,455
808 Added 13.82%
6,655 $905,000
Q2 2017

Aug 14, 2017
BUY
N/A
5,847
5,847 $709,000

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2.01B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email